What One Genomics does

One Genomics is a privately held biotechnology research company founded in 2023 and headquartered in San Francisco, with additional operations in Boston and Tokyo. The company builds an integrated platform that combines a high-precision, fine-tunable CRISPR design platform — anchored by a patented 'Safeguard' methodology — with frontier generative AI and agentic systems trained on a self-described multi-layer causal in vivo data substrate, supplemented by high-capacity genome delivery systems rated at 100x conventional payload limits. The platform targets programmable, multi-factor cellular reprogramming and human de-aging applications, addressing documented limitations of conventional genome engineering including off-target mutations, bystander effects, and inability to fine-tune editing outcomes, with company-disclosed metrics of 100x safety, 7x efficiency, and 3000x precision improvements.

The company is co-founded by Harvard Professor of Genetics George Church, PhD, alongside CEO Diana Luan (MBA), Masaki Kawamata, PhD, Motoshi Hayano, PhD, and Shoko Iwai, PhD. Customers and collaborators are academic medical centers, research institutions, and foundations engaged in regenerative medicine and iPS cell engineering. The company's go-to-market is relationship-driven and licensing-oriented: as a research-stage biotech with no publicly disclosed pricing or product sales, One Genomics distributes its technology through strategic research collaboration agreements and platform licensing — most prominently a January 2026 collaboration with the CiRA Foundation (established by Kyoto University) to apply its CRISPR design platform to human iPS cell engineering for regenerative medicine applications.

The company's investor base spans US deep-tech operators (Michael Antonov via Formic Ventures; Oculus founder) and Japan institutional capital (SBXi, University of Tokyo IPC, Keio Innovation, FFG Venture Japan), reflecting a cross-border commercialization strategy anchored in the Japanese regenerative medicine and longevity ecosystems. As of the latest disclosures the company has no reported revenue, operates with 1-10 employees, and holds one granted patent on the Safeguard approach, with its only recorded funding event a 2024 round led by SBXi.

Name

One Genomics

Legal name

One Genomics Inc

Website

https://onegenomics.co

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

One Genomics is a San Francisco-based biotechnology research company founded in 2023 that combines a patented high-precision CRISPR design platform with frontier AI modeling and 100x-capacity delivery systems to advance programmable cellular reprogramming and de-aging research for academic and regenerative-medicine partners.

Ownership category

akta.pro rank

Product category

Genomics Research Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

Keywords

• Genome editing platform
• CRISPR design tools
• Precision gene engineering
• Cellular reprogramming
• Regenerative medicine

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Strategic Research Collaborations: Revenue generated through strategic research collaboration agreements with academic institutions, foundations, and biotech partners to advance precision genome engineering technologies.
2. Platform Licensing: Licensing of proprietary CRISPR design platform technologies including the patented Safeguard approach to research and clinical partners.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

One Genomics develops a high-precision, fine-tunable CRISPR design platform integrated with frontier AI modeling and high-capacity delivery systems for cellular reprogramming and de-aging applications. Its patented Safeguard approach addresses off-target mutations and bystander effects that limit conventional CRISPR tools, while the AI platform leverages multi-layer causal in vivo data to enable programmable, multi-factor human de-aging interventions.

Product overview

One Genomics offers an integrated platform combining frontier AI modeling with cellular reprogramming and high-precision genome engineering for de-aging applications. The core offerings include a High-Precision CRISPR Design Platform (with patented Safeguard technology), Frontier AI Modeling Platform utilizing multi-layer causal in vivo data and generative AI/agentic systems, and High-Capacity Delivery Systems enabling 100x payload delivery for multi-gene rejuvenation programs across tissues.

Differentiator

Problem solved

Functional benefit

Products and services

• High-Precision CRISPR Design Platform A proprietary, fine-tunable CRISPR design platform with a patented Safeguard methodology that addresses off-target mutations and bystander effects to deliver greater precision, controllability, and reliability for cellular and clinical genome engineering applications. It is offered to research institutions, foundations, and biotech partners for licensing and strategic collaboration.
• Frontier AI Modeling Platform A first-of-its-kind multi-layer causal in vivo data platform that applies frontier generative AI models and agentic systems to systemic human biology, enabling programmable, multi-factor human de-aging research. It serves as the analytical and modeling layer underlying the company's cellular reprogramming programs.
• High-Capacity Delivery Systems Large-scale genome delivery systems engineered at 100x conventional payload limits, enabling durable yet precisely controllable multi-gene rejuvenation programs delivered across the body, including traditionally hard-to-reach tissues. They overcome the conventional delivery bottleneck for multi-gene interventions.
• Strategic Research Collaboration Agreements Direct research collaboration engagements through which One Genomics contributes its high-precision CRISPR design platform and Safeguard technology to partners such as the CiRA Foundation to advance cellular and clinical applications in regenerative medicine and iPS cell engineering.

Quantifiable outcome

• 100x improvement in safety over conventional genome engineering approaches
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• CiRA FoundationcoreStrategic or Co-development Partner · 8 January 2026Strategic research collaboration to advance precision genome engineering technologies. One Genomics contributes its proprietary high-precision, fine-tunable CRISPR design platform including patented Safeguard approach. CiRA Foundation applies these technologies in human iPS cells drawing on world-leading expertise in regenerative medicine. Goal is to improve engineering performance across clinically relevant cellular contexts with greater precision, controllability, and reliability for cellular and clinical applications.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Prime Medicine: Clinical-stage biotech developing prime editing, a search-and-replace genome editing technology. Directly comparable as a next-generation precision editing platform company working to expand the addressable editing scope.
• Beam Therapeutics: Clinical-stage biotechnology company developing base editing therapies, a next-generation CRISPR-derived approach. Directly comparable as a precision genome editing platform company pursuing differentiated editing chemistries.
• Verve Therapeutics: Clinical-stage biotech developing in vivo gene editing medicines for cardiovascular disease. Directly comparable as an in vivo CRISPR editing company working on delivery and precise editing for systemic indications.
• Editas Medicine: Clinical-stage CRISPR gene editing company developing engineered cell therapies and in vivo gene editing medicines. Directly comparable as a CRISPR platform company targeting therapeutic applications with proprietary editing technology.
• Intellia Therapeutics: Clinical-stage genome editing company developing in vivo and ex vivo CRISPR/Cas9 therapies. Directly comparable as a CRISPR therapeutics company with platform-based editing technology applied to genetic disease.
• Tessera Therapeutics: Stealth-mode biotech pioneering 'gene writing' — a multi-letter rewriting of the genome. Highly comparable as a next-generation precision editing platform pursuing programmable multi-factor genome changes.
• Caribou Biosciences: Clinical-stage CRISPR genome and allogeneic cell therapy company. Directly comparable as a CRISPR platform company applying next-generation editing to therapeutic applications.
• Mammoth Biosciences: CRISPR-based platform company developing in vivo gene editing therapeutics and diagnostics. Directly comparable as a CRISPR platform company targeting both therapeutic and research applications of novel CRISPR systems.

Broad incumbents

• Synthego: Established provider of CRISPR genome engineering tools, including synthetic guide RNAs and cell lines. Comparable as a supplier of CRISPR infrastructure underpinning genome editing R&D across the industry.

Emerging players

• Locus Biosciences: Clinical-stage biotechnology company developing precision antimicrobial therapies using engineered bacteriophage and CRISPR-Cas3. Partially comparable as a CRISPR-based platform company developing novel editing-derived therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about One Genomics